Why IMU is a multi multi bagger, page-26421

Correct IBBY, IMUGENE 1 had a vast and growing retail following, which at the time was not only a novel drug but with management sounding out continually how good this was going sounded to good to be true. To be fair myself and a lot of early investors done well on the way up. The only losers were the ones who held but didn’t sell any.
Imugene 2 is just at the start of 1, no saying this is not going to be successful this time around but as you said will be a long way down the road. The biggest problem will be the trust of management, once bitten twice shy. Hopefully for investors this turns out right at the end.